Evaluation of Micro-RNA Expression Profiling Level as Biomarkers for Diagnosis and Gene Sequencing in Patients Suffering from Breast Cancer

Rasha H. Al-Rikabi, Nagui H. Fares, Mahmmad A. AL Faham, Abdel Hady A. Abdel Wahab

Abstract


Background: Human bloodstream microRNAs (miRNAs) have emerged as a promising predictive and diagnostic biomarker for a range of cancers, including breast cancer. Our objective was to look into new miRNA biomarkers for diagnosis in the serum of patients with breast cancer and track the expression levels at different stages using miRNA profiling.

Methods: 53 breast cancer patients and 10 healthy controls had blood samples tested for three miRNAs. miRNAs were extracted from blood and evaluated using real-time quantitative polymerase chain reaction. After extracting genomic DNA, miRNA primer-produced PCR products were sequenced to discover point mutations that may contribute to the illness.

Results: After examining miR195, miR200b, and miR331, breast cancer patients had a significantly lower miR195 level than healthy persons. In addition, miR200b expression levels were significantly lower in breast cancer patients than in healthy individuals. In advanced stages, miR331 expression was substantially higher than in healthy people.

Conclusion: The findings of our study demonstrated a significant association between the expression of miRNAs and the prognosis of breast cancer. Additional research is necessary to study better the correlation between these circulating miRNAs and the stages of breast cancer.

Keywords: Breast cancer; Circulating miRNAs; miR195; miR200b; miR331 RT PCR; Gene Sequencing  


Full Text:

PDF

References


Thompson A, Brennan K, Cox A, Harcourt D. Harris A, et al. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Research,(2008); 2(12): 348-365.

Taplin S, Abraham L, Barlow W. Mammography facility characteristics associated with interpretive accuracy of screening mammography. Journal National Cancer Institute, (2008);100(12),876 – 887.

Uehara M, Kinoshita T, Hojo T. Akashi-Tanaka S, Iwamoto E, et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15–3 (CA 15–3) in breast cancer. International Journal Clinical Oncology, (2007);13,447– 451.

Kinoshita T, Hojo T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15–3 (CA 15–3) in breast cancer. International Journal Clinical Oncology, (2007);13(9) :447– 451.

Feng Y, Spezia M, Huang S, Yuan C, Zeng Z,et al. Breast Cancer Development and Progression: Risk Factors, Cancer Stem Cells, Signaling Pathways, Genomics, and Molecular Pathogenesis. Genes Disease (2018); 5(2):77–106.

Elango R, Alsaleh K, Vishnubalaji R, Manikandan M, Ali A, et al. MicroRNA Expression Profiling on Paired Primary and Lymph Node Metastatic Breast Cancer Revealed Distinct microRNA Profile Associated With LNM. Frontiers in Oncology (2020);19;10:756.

Treiber T, Treiber N, Meister G. Regulation of microRNA Biogenesis and its Crosstalk With Other Cellular Pathways. Nature Reviews Molecular Cell Biology, (2019); 20(1):5–20.

Krol J, Loedige I, Filipowicz W. The Widespread Regulation of microRNA Biogenesis, Function and Decay. Nature Reviews Genetics, (2010);11(9):597–610.

Czimmerer Z, Hulvely J, Simandi Z, Varallyay E, Havelda Z, et al. Versatile Method to Design StemLoop Primer-Based Quantitative PCR Assays for Detecting Small Regulatory RNA Molecules. PLoS One, (2013);8(1), e55168.

Abak A, Amini S, Estiar MA, Montazeri V, Sakhinia E, et al. Analysis of miRNA-221 Expression Level in Tumors and Marginal Biopsies From Patients With Breast Cancer (Cross-Sectional Observational Study). Clinical Labortory,(2018); 64(1):169–175.

Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology, (2004); 3: Article 3.

Bahmanpour Z, Sheervalilou R, Choupani J, Shekari K, Montazeri V, et al. A new insight on serum microRNA expression as novel biomarkers in breast cancer patients. Journal Cell Physiology, (2019);234(11):19199-19211.

Bartels C, Tsongalis G. MicroRNAs: novel biomarkers for human cancer. Clinical Chemistry, (2009); 55(4):623-631.

Opstal-van W, Rodenburg W, Pennings J, van Oostrom C, Beijnen J, et al. A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. International Journal Molecular Sciences,(2012); 13(10):13587-13604.

Jang K, Ahn H, Sim J, Han H, Abdul R. et al. Loss of microRNA-200a expression correlates with tumor progression in breast cancer. Translational Research,(2014); 163(3), 242-251.

Hafez M, Hassan Z, Zekri A, Gaber A, Al Rejaie S, et al. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pacific Journal of Cancer Prevention,(2012);13(2), 591-598.

Pencheva N, Tavazoie S. Control of metastatic progression by microRNA regulatory networks. Nature Cell Biology, (2013); 15: 546-554.

Li D, Zhao Y, Liu C, Chen X, Qi, Y, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clinical Cancer Research,(2011); 17:1722–1730.

Hannafon B, Sebastiani, P, de las Morenas, A, Lu, J, Rosenberg, C. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Research,(2011); 13 (2): R24.

Zhao F, Dou, Y, Wang X, Han D, Lv Z, et al. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer. Molecular Biology Report, (2014); 41(9):5913-5922.

Deng H, Guo Y, Song H, Xiao B, Sun W, et al. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetic regulation in gastric cancer. Gene,(2013); 518 (2);351–359.

Yu W, Liang X, Li X, Zhang Y, Sun Z, et al. MicroRNA-195: a review of its role in cancers. Oncotargets and therapy,(2018); 11: 7109–7123.

Shao Y, Sun X, He Y, Liu C, Liu H, et al. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS One,(2015); 10 (7):e133830.

Nadeem F, Hanif M, Ahmed A, Jamal Q, Khan A. Clinicopathological features associated with MiRNA-195 expression in patients with breast cancer: evidence of a potential biomarker. Pakistan Journal of Medical Sciences, (2017); 33 (5), 1242–1247.

Luo Q, Wei C, Li X, Li J, Chen L, et al. MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncology Report,(2014); 31 (3), 1096–1102.

Kumar V, Abbas A.K, Fausto N, Aster J. Robbins, and Cotran Pathologic Basis of Disease Elsevier: health sciences, (2014); 9th ed.

Ye F, Tang H, Liu Q. miR-200b as a prognostic factor in breast cancer targets multiple members of the RAB family. Journal of Translational Medicine,(2014); 12(17):1-10.

Hong H, Yu H, Yuan J, Guo C, Cao H, et al. MicroRNA-200b Impacts Breast Cancer Cell Migration and Invasion by Regulating Ezrin-Radixin-Moesin. Medical Sciences Monitor,(2016); 8(22):1946-1952.

He M, Liu Y, Deng X, Qi S, Sun X, et al . Down-regulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells. Prostate (2013), 73(10):1048–1056.

Cai Z, Zhang S, Zhang H, Zhou Y, Wu H, et al. Aberrant expression of microRNAs involved in epithelial-mesenchymal transition of HT-29 cell line. Cell Biology International,(2013).; 37(7):669–674.

Pacurari M, Addison J, Bondalapati N, Wan Y, Luo D, et al. The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. International Journal Oncology, (2013); 43:548–560.

Yoshino H, Enokida H, Itesako T, Tatarano S, Kinoshita T, et al. Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. Juornal Human Genet. (2013);

:508–516.

Castilla M, Díaz-Martín J, Sarrió D, Romero-Pérez L, López-García M, et al. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One. (2012);7(10):e47709.

Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene, (2011); 31:2062–2074.

Kang L, Mao J, Tao Y, Song B, Ma W, et al. MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway. Cancer Sciences,(2015); 106:700–708.

Papadopoulos E., Papachristopoulou G, Ardavanis A, Scorilas A. A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance. Clinical Biochemistry. (2018); 60:24-32.

Chang R, Yang H, Fang F, Xu J, Yang L. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology,(2014);60: 1251 –63.

Chen X, Luo H, Li X, Tian X, Peng B, et al. miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer. Carcinogenesis (2018);39(8):1006–1015.

Fujii T, Shimada K, Asano A, Tatsumi Y, Yamaguchi N, et al. MicroRNA331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2. International Journal Molecular Sciences, (2016);17(8):13-51.

Zhao D, Sui Y, Zheng X. MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer. Oncology Report,(2016); 35(2):1075–1082.

Buranjiang G, Kuerban R, Abuduwanke A, Li X, Kuerban G. MicroRNA-331-3p inhibits proliferation and metastasis of ovarian cancer by targeting RCC2. Archives of Medical Sciences,(2019); 15(6):1520–1529.

Butrym A, Rybka J, Baczyńska D, Tukiendorf A, Kuliczkowski K, et al. Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. Biomarkers in Medicine,(2018); 9(5):453-460.

Schwarzenbach H, Nishida N, Calin G, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nature Reviews Clinical Oncology,(2014);11(3): 145–156.

Roth C, Rack B, Muller, V. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research,(2010);12:R90.

Van Schooneveld E, Wouters M, van der Auwera I, Peeters D, Wildiers H, et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers, Breast Cancer Research, (2012); 14 (1) R34.

Pigati L, Yaddanapudi S, Iyengar R. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One,(2010);5: e13515.

Witwer K. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clinical Chemistry, (2015);61(1):56-63.

Valadi H, Ekstrom K, Bossios A. Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, (2007); 9:654–659.

Gallo A, Tandon M, Alevizos, I. The majority of microRNAs detectable in serum and saliva are concentrated in exosomes. PLoS One, (2012);7: e30679.

Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochemistry Sciences (2012); 37: 460–465.

Arroyo J. Chevillet J. Kroh E. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proceedings of the National Academy of Sciences of the United States of America,(2011);108(12): 5003–5008.

Pritchard C, Kroh E, Wood B. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prevention Research (Phila) (2012); 5(3):492–497.




DOI: http://dx.doi.org/10.62940/als.v11i3.2910

Refbacks

  • There are currently no refbacks.